Related Experiment Video
Updated: May 13, 2026
09:33
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
New prognostic markers in neuroblastoma
Samuel Navarro1, Marta Piqueras, Eva Villamón
1Department of Pathology, Medical School, University of Valencia , Avda. Blasco Ibañez 15 Valencia 46010 , Spain +34 96 3864146 ; +34 96 3864173 ; rosa.noguera@uv.es.
Expert Opinion on Medical Diagnostics
|March 14, 2013
Summary
Neuroblastoma treatment relies on understanding its heterogeneity. This review covers current and future prognostic factors to improve risk-adapted therapy and patient outcomes.
Area of Science:
- Pediatric Oncology
- Cancer Biology
Background:
- Neuroblastoma exhibits significant clinical and biological heterogeneity.
- Prognosis for neuroblastoma varies widely based on age, disease stage, and tumor biology.
Purpose of the Study:
- To review current prognostic factors for risk-adapted neuroblastoma therapy.
- To discuss evolving prognostic factors for future treatment strategies.
Main Methods:
- Literature review focusing on the last six years.
- Analysis of clinical management and prognostic indicators.
Main Results:
- Currently used prognostic factors guide risk-adapted therapy.
- Evolving factors are crucial for developing future treatment schemes.
Conclusions:
- Integrating clinical and biomarker data can create predictive models for personalized neuroblastoma therapy.
- These models may identify molecular targets for specific treatments.
